Granted Patent
B2
US 12,274,711 · App. 18/147,134 · Granted Apr 15, 2025
Method of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors
Inventors:
Tatiana I. Vener (Stirling, NJ); Carlo C. Derecho (Lakehurst, NJ); John F. Palma (Alamo, CA); Mical Raponi (San Francisco, CA)
Assignee:
Janssen Pharmaceutica NV
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients.
Claims (18)
1. A method for prescribing tipifarnib to a subject diagnosed with a disorder, the method comprising:
evaluating expression of RAS guanyl releasing protein 1 (RASGRP1) and aprataxin (APTX) in a blood sample of said subject by using a polymerase chain reaction to achieve an amplification of signals from ribonucleic acid targets using at least one primer from the group consisting of
(i) 5′-CGCTTCCGATTGGGCTAC-3′
(ii) 5′-AGAATCAAAATCCTGGCTGATC-3′
(iii) 5′-CTGGACGATCTCATTGACAGC-3′
and
(iv) 5′-CTTGCAACAGTTGGTTACTTCG-3′.
2. The method of claim 1 , wherein the evaluating comprises estimating a ratio of expression levels of RASGRP1 relative to APTX.
3. The method of claim 1 , wherein the essay evaluating is performed in a single tube in a multiplex format.
4. The method of claim 1 , wherein the evaluating comprises determining a ratio of expression levels of RASGRP1 relative to APTX using an external control.
5. The method of claim 4 , wherein the ratio of expression levels of RASGRP1 relative to APTX is compared to a ΔΔCt threshold value of about 5.2.
6. The method of claim 4 , wherein the ratio of expression levels of RASGRP1 relative to APTX is compared to a ΔΔCt threshold value of about 4.7.
7. The method of claim 4 , wherein the ratio of expression levels of RASGRP1 relative to APTX is compared to a threshold value corresponding to a specified sensitivity or specificity or a maximized sum of sensitivity and specificity in an ROC analysis.
8. The method of claim 7 , wherein the threshold value is selected to correspond to an area under the curve that is about 70% or more in the ROC analysis.
9. The method of claim 4 , wherein the external control is selected from the group consisting of one or more reference cell lines, JY RNA, Universal RNA, a standardized RNA reference, and a reference patient sample.
10. The method of claim 4 , comprising prescribing tipifarnib to the subject if the ratio of expression levels of RASGRP 1 relative to APTX in the subject is greater than a threshold value.
11. The method of claim 6 , wherein the prescribing of tipifarnib further comprises prescribing an agent synergistic with tipifarnib, wherein the agent is selected from the group consisting of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab, cisplatinum, and derivatives thereof.
12. The method of claim 11 , wherein the agent is etoposide.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 28, 2025
From: VENER, TATIANA I.; DERECHO, CARLO C.; RAPONI, MICAL; PALMA, JOHN F.
To: VERIDEX, LLC
Reel/Frame 070028/0367 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 28, 2025
From: JANSSEN DIAGNOSTICS, LLC
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 070028/0672 →
CHANGE OF NAME
Recorded Jan 28, 2025
From: VERIDEX, LLC
To: JANSSEN DIAGNOSTICS, LLC
Reel/Frame 070030/0827 →
Continuity (4)
Continuation
PCTUS2011045693
· Jul 28, 2011
Provisional Application
61368453
· Jul 28, 2010
References Cited (91)
US 5922571A
· Hillman
· 1999
[cited by applicant]
US 7119186B2
· Tsuji
· 2006
[cited by applicant]
US 7932036B1
· Raponi et al.
· 2011
[cited by applicant]
US 8249814B2
· Liew et al.
· 2012
[cited by applicant]
US 20040110792A1
· Raponi
· 2004
[cited by applicant]
US 20050003422A1
· Reponi
· 2005
[cited by applicant]
US 20060111358A1
· De Bont et al.
· 2006
[cited by applicant]
US 20070048782A1
· Raponi
· 2007
[cited by applicant]
US 20080280297A1
· Dalla-Favera
· 2008
[cited by applicant]
EP 1767656A2
· 2007
[cited by applicant]
EP 1478773B1
· 2007
[cited by applicant]
JP 2005522990A
· 2005
[cited by applicant]
JP 2006503871A
· 2006
[cited by applicant]
JP 2009512440A
· 2009
[cited by applicant]
MX PA04004072
· 2004
[cited by applicant]
WO 2004032935A1
· 2004
[cited by applicant]
WO 2007048074A1
· 2007
[cited by applicant]
WO 2008011279A1
· 2008
[cited by applicant]
WO 2008112749A1
· 2008
[cited by applicant]
Genbank Accession AY634315 (NCBI, NLM, 2007).
[cited by examiner]
Ahel et al., “The Neurodegenerative Disease Protein Aprataxin Resolves Abortive DNA Ligation Intermediates”, Nature, 2006, vol. 443, pp. 713-716.
[cited by applicant]
Akoben, “Review Article, Understanding Diagnostic Tests 3: Receiver Operating Characteristic Curves”, Acta Paediatrica, 2007, vol. 96, No. 5, pp. 644-647.
[cited by applicant]
Bacher et al., “Briefings In Functional Genomics And Proteomics Advance Access”, Perspectives Of Gene Expression Profiling For Diagnosis And Therapy In Haematological Malignancies, 2009, pp. 1-10.
[cited by applicant]
Baylin et al., Nature Clinical Practice, 2005, vol. 2, pp. S1-S3.
[cited by applicant]
Bivona et al., “Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1”, Nature, 2003, vol. 424, pp. 694-698.
[cited by applicant]
Bos, “Ras Oncogenes in Human Cancer: A Review”, Cancer Res, 1989, vol. 49, pp. 4682-4689.
[cited by applicant]
Bullinger et al., “Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia”, N. Engl. J. Med, 2004, vol. 350, pp. 1605-1616.
[cited by applicant]
Burger et al., “Activating Mutations In C-KIT And Pdgfralpha Are Exclusively Found In Gastrointestinal Stromal Tumors And Not In Other Tumors Overexpressing These Imatinib Mesylate Target Genes”, Cancer Biol Ther, 2005,…
[cited by applicant]
Chang et al., “Gene Expression Profiling For The Prediction Of Therapeutic Response To Docetaxel In Patients With Breast Cancer”, Lancet, 2003, vol. 362, pp. 362-369.
[cited by applicant]
Chen et al., “FLT3/ITD Mutation Signaling Includes Suppression Of SHP-1”, J. Biol. Chem., 2005, vol. 280, pp. 5361-5369.
[cited by applicant]
Cox et al., “Famesyltransferase Inhibitors: Promises And Realities”, Curr. Opin. Pharmacol., 2002, vol. 2, pp. 388-393.
[cited by applicant]
Cronin et al., Clinical Chemistry, 2004, vol. 50, pp. 1464-1471.
[cited by applicant]
Ebinu et al., “RasGRP, A Ras Guanyl Nucleotide—Releasing Protein With Calcium- And Diacylglycerol-Binding Motifs”, Science, 1998, vol. 280, pp. 1082-1086.
[cited by applicant]
Ehmann et al., “Detection of N-RAS and K-RAS In Their Active GTP-Bound Form In Acute Myeloid Leukemia Without Activating RAS Mutations”, Leuk. Lymphoma, 2006, vol. 47, pp. 1387-1391.
[cited by applicant]
End et al., “Characterization Of The Antitumor Effects Of The Selective Famesyl Protein Transferase Inhibitor R115777 In Vivo And In Vitro”, Cancer Res, 2001, vol. 61, pp. 131-137.
[cited by applicant]
Feldkamp et al., “Isotype-Specific Rasgtp-Levels Predict The Efficacy Of Famesyl Transferase Inhibitors Against Human Astrocytomas Regardless Of Ras Mutational Status”, Cancer Res, 2001, vol. 61, pp. 4425-4431.
[cited by applicant]
Geman et al., “Classifying gene expression profiles from pairwise mRNA comparisons”, Stat Appl Genet Mol Biol, 2004, vol. 3, 30, pp. 1-19.
[cited by applicant]
Harousseau et al., A Randomized Phase 3 Study Of Tipifarnib Compared With Best Supportive Care, Including Hydroxyurea, In The Treatment Of Newly Diagnosed Acute Myeloid Leukemia In Patients 70 Years Or Older, Blood, 200…
[cited by applicant]
Hollerman et al., “Gene-Expression Patterns In Drug-Resistant Acute Lymphoblastic Leukemia Cells And Response To Treatment”, N. Engl. J. Med., 2004, vol. 351, pp. 533-542.
[cited by applicant]
Illmer et al., “Activation of the RAS Pathway Is Predictive For A Chemosensitive Phenotype Of Acute Myelogenous Leukemia Blasts”, Clin Cancer Res, 2005, vol. 11, pp. 3217-3322.
[cited by applicant]
International Search Report PCT/US11/45693 Mailed Date Mar. 8, 2012.
[cited by applicant]
Jansen et al., “Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling”, J. Clin. Oncol., 2005, vol. 23, pp. 732-740.
[cited by applicant]
Karp et al., “Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML): Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults =Age 70 Who Are Not Candidates…
[cited by applicant]
Karp et al., “Active Oral Regimen For Elderly Adults With Newly Diagnosed Acute Myelogenousleukemia: A Preclinical And Phase 1 Trial Of The Famesyltransferase Inhibitor Tipifamib (R115777, Zamestra) Combined With Etopos…
[cited by applicant]
Karp et al., “Clinical And Biologic Activity Of The Famesyl transferase Inhibitor R115777 in Adults With Refractory And Relapsed Acute Leukemias: A Phase 1 Clinical-Laboratory Correlative Trial”, Blood, 2001, vol. 97, p…
[cited by applicant]
Karp et al., “Multi-institutional Phase 2 Clinical And Pharmacogenomic Trial Of Tipifarnib Plus Etoposide For Elderly Adults With Newly Diagnosed Acute Myelogenous Leukemia”, Blood, 2011, vol. 119, pp. 55-63.
[cited by applicant]
Karp et al., Biologies: Targets & Therapy 2008, vol. 2, pp. 491-500.
[cited by applicant]
Karp et al., History of Changes for Study: NCT00112853 Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, 2010, pp. 1-10.
[cited by applicant]
Kawasaki et al., “A Rap Guanine Nucleotide Exchange Factor Enriched Highly In The Basal Ganglia”, Proc Natl Acad Sci, 1998, vol. 95, pp. 13278-13283.
[cited by applicant]
Lancet et al., “A phase II Study Of The Famesyltransferase Inhibitor Tipifamib In Poor-Risk And Elderly Patients With Previously Untreated Acute Myelogenous Leukemia”, Blood, Feb. 15, 2007; 109(4): 1387-1394; Prepublish…
[cited by applicant]
Leith et al., “Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest …
[cited by applicant]
Livak et al., Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-DDCT Method. Methods, 2001, 25, pp. 402-408.
[cited by applicant]
Lossos et al., “Prediction of survival in diffuse large B cell lymphoma based on the expression of six genes”, N. Engl. J. Med., 2004, vol. 350, pp. 1828-1837.
[cited by applicant]
Lubet et al., “Effects Of The Famesyl Transferase Inhibitor R115777 (Zamestra) On Mammary Carcinogenesis: Prevention, Therapy, And Role Of HaRas Mutations”, Mol. Cancer Ther., 2006, vol. 5, pp. 1073-1078.
[cited by applicant]
Lynch et al., “Activating Mutations In The Epidermal Growth Factor Receptor Underlying Responsiveness Of Non-Small-Cell Lung Cancer To Gefitinib”, N. Engl. J. Med., 2004, vol. 350, pp. 2129-2139.
[cited by applicant]
Ma et al., “A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen”, Cancer Cell, 2004, vol. 5, pp. 607-616.
[cited by applicant]
Martinelli et al., Correlation of RASGRP1/APTX Ratio With Clinical Response And Survival In AML Patients Treated With Tipifarnibbortezomib Combination, Journal of Clinical, 2010, Suppl. 6550, pp. 1-5.
[cited by applicant]
Mesa et al., “Tipifamib: Famesyl Transferase Inhibition At A Crossroads”, Expert Rev Anticancer Ther., 2006, vol. 6, No. 3, pp. 313-319.
[cited by applicant]
Miyake, “Kazunori: Early Diagnosis and Clinical Testing”, Journal of the Japanese Society of Internal Medicine, 2005, vol. 94, No. 12, pp. 2467-2472.
[cited by applicant]
Moroni et al., “Gene Copy Number For Epidermal Growth Factor Receptor (EGFR) And Clinical Response To Antiegfr Treatment In Colorectal Cancer: A Cohort Study”, Lancet Oncol., 2005, vol. 6, pp. 279-286.
[cited by applicant]
Nippon Suisan Gakkaishi, “Special feature: Real-Time Monitoring of Marine Microorganisms”, Principles and applications of real-time quantitative PCR, 2007, vol. 37, No. 2, pp. 292-295.
[cited by applicant]
Papayannidis et al., Abstract #743: RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML), Cancer Research, 200…
[cited by applicant]
Perez De Castro et al., “A Ras activation in Jurkat T cells following low-grade stimulation of the T-cell receptor is specific to N-Ras and occurs only on the Golgi apparatus”, Mol. Cell Biol., 2004, vol. 24, pp. 3485-3…
[cited by applicant]
Petersen et al., “Comparison of Nucleic Acid Targets Prepared From Total RNA Or Poly(A) RNA For DNA Oligonucleotide Microarray Hybridization”, Anal. Biochem., 2007, vol. 366, pp. 46-58.
[cited by applicant]
Potti et al., “Genomic signatures to guide the use of chemotherapeutics”, Nat Med, 2006, vol. 12, pp. 1294-1300.
[cited by applicant]
Rao et al., “Phase III Double-Blind Placebo-Controlled Study of Famesyl Transferase Inhibitor R115777 with Patients With Refractory Advanced Colorectal”, Cancer J Clin Oncol, 2004, vol. 22, pp. 3950-3957.
[cited by applicant]
Raponi et al., “A 2-Gene Classifier For Predicting Response To The Famesyltransferase Inhibitor Tipifamib In Acute Myeloid Leukemia”, Blood, 2008, vol. 111, pp. 2589-2596.
[cited by applicant]
Raponi et al., “Identification Of Molecular Predictors Of Response In A Study Of Tipifanib Treatment In Relapsed And Refractory Acute Myelogenous Leukemia”, Clin Cancer Res., 2007, vol. 13, pp. 2254-2260.
[cited by applicant]
Raponi et al., “RASGRP1:APTX Gene Expression Ratio Enriches for Responders to the Combination of Tipifarnib and Etoposide in Elderly Newly Diagnosed AML”, Blood, 2009, vol. 114, Issue 22, abstract 4154.
[cited by applicant]
Reuter et al., “Targeting The Ras Signaling Pathway: A Rational, Mechanism-Based Treatment For Hematologic Malignancies?”, Blood, 2000, vol. 96, pp. 1655-1669.
[cited by applicant]
Reuther et al., “Leukemia-Associated Rho Guanine Nucleotide Exchange Factor, A Dbl Family Protein Found Mutated In Leukemia, Causes Transformation By Activation Of RhoA”, J Biol Chem, 2001, vol. 276, pp. 27145-27151.
[cited by applicant]
Reuther et al., “RasGRP4 is A Novel Ras Activator Isolated From Acute Myeloid Leukemia”, J Biol Chem, 2002, vol. 277, pp. 30508-30514.
[cited by applicant]
Rolland et al., “Phase II Trial And Prediction Of Response Of Single Agent Tipifarnib In Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Groupe d'Etude des Lymphomes de l′ Adult trial”, Cancer Chemother Pharma…
[cited by applicant]
Rosenwald et al., “The Use Of Molecular Profiling To Predict Survival After Chemotherapy For Diffuse Large-B-Cell Lymphoma”, N Engl J Med., 2002, vol. 346, pp. 1937-1947.
[cited by applicant]
Rowinsky et al., “Ras Protein Famesyltransferase: A Strategic Target For Anticancer Therapeutic Development”, J Clin Oncol., 1999, vol. 17, pp. 3631-3652.
[cited by applicant]
Sahai et al., “RHO-GTPases and cancer”, Nat Rev Cancer, 2002, vol. 2, pp. 133-142.
[cited by applicant]
Sakhinia et al., “Mortality After Surgery In Europe: A 7 Day Cohort Study”, J. Clin. Pathol., 2006, vol. 59, pp. 1059-1065.
[cited by applicant]
Seidman et al., “Weekly Trastuzumab And Paclitaxel Therapy For Metastatic Breast Cancer With Analysis Of Efficacy By HER2 Immunophenotype And Gene Amplification”, J Clin Oncol., 2001, vol. 19, pp. 2587-2595.
[cited by applicant]
Shipp et al., “Diffuse Large B-cell Lymphoma Outcome Prediction By Gene-Expression Profiling And Supervised Machine Learning”, Nat Med., 2002, vol. 8, pp. 68-74.
[cited by applicant]
Solit et al., “BRAF Mutation Predicts Sensitivity To MEK Inhibition”, Nature, 2006, vol. 439, pp. 358-362.
[cited by applicant]
Sterpetti et al., “Activation Of The Lbc Rho Exchange Factor Proto—Oncogene By Truncation Of An Extended C Terminus That Regulates Transformation And Targeting”, Mol Cell Biol., 1999, vol. 19, pp. 1334-1345.
[cited by applicant]
Stone, “Regulation Of Ras In Lymphocytes: Get A GRP”, Biochem Soc Trans, 2006, vol. 34, pp. 858-861.
[cited by applicant]
Tognon et al., “Regulation Of RasGRP Via A Phorbol Ester- Responsive C1 Domain”, Mol. Cell Biol., 1998, vol. 18, pp. 6995-7008.
[cited by applicant]
Tsao et al., “Erlotinib in Lung Cancer—Molecular And Clinical Predictors Of Outcome”, N Engl J Med., 2005, vol. 353, pp. 133-144.
[cited by applicant]
Van Cutsem et al., “Phase III Trial Of Gemcitabine Plus Tipifamib Compared With Gemcitabine Plus Placebo In Advanced Pancreatic Cancer”, J Clin Oncol., 2004, vol. 22, pp. 1430-1438.
[cited by applicant]
Watters et al., “Developing gene expression signatures of pathway deregulation in tumors”, Mol Cancer Ther., 2006, vol. 5, pp. 2444-2449.
[cited by applicant]
Weinstein et al., “Mechanisms of disease: Oncogene addiction—a rationale for molecular targeting in cancer therapy”, Nat Clin Pract Oncol., 2006, vol. 3, pp. 448-457.
[cited by applicant]
Whyte et al., “K- and N-Ras are geranylgeranylated in cells treated with famesyl protein transferase inhibitors”, J Biol Chem., 1997, vol. 272, pp. 14459-14464.
[cited by applicant]
Yeoh et al., “Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling”, Cancer Cell, 2002, vol. 1, pp. 133-143.
[cited by applicant]